HK1222396A1 - 作為選擇性蛋白質激酶抑制劑之苯並咪唑衍生物 - Google Patents

作為選擇性蛋白質激酶抑制劑之苯並咪唑衍生物

Info

Publication number
HK1222396A1
HK1222396A1 HK16110610.1A HK16110610A HK1222396A1 HK 1222396 A1 HK1222396 A1 HK 1222396A1 HK 16110610 A HK16110610 A HK 16110610A HK 1222396 A1 HK1222396 A1 HK 1222396A1
Authority
HK
Hong Kong
Prior art keywords
selective
kinase inhibitors
benzimidazole derivatives
proteine kinase
proteine
Prior art date
Application number
HK16110610.1A
Other languages
English (en)
Inventor
Alain Moussy
Abdellah Benjahad
Claire Schalon
Didier Pez
Emmanuel Chevenier
Franck Sanderinelli
Jason Martin
Willy Picoul
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of HK1222396A1 publication Critical patent/HK1222396A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
HK16110610.1A 2013-06-20 2016-09-06 作為選擇性蛋白質激酶抑制劑之苯並咪唑衍生物 HK1222396A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305837 2013-06-20
PCT/EP2014/063045 WO2014202763A1 (en) 2013-06-20 2014-06-20 Benzimidazole derivatives as selective proteine kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1222396A1 true HK1222396A1 (zh) 2017-06-30

Family

ID=48741004

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110610.1A HK1222396A1 (zh) 2013-06-20 2016-09-06 作為選擇性蛋白質激酶抑制劑之苯並咪唑衍生物

Country Status (6)

Country Link
US (1) US10202370B2 (zh)
EP (1) EP3010906B1 (zh)
AR (1) AR096654A1 (zh)
HK (1) HK1222396A1 (zh)
TW (1) TW201534597A (zh)
WO (1) WO2014202763A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
KR20220124176A (ko) 2019-12-06 2022-09-13 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 치환된 테트라하이드로푸란
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021242790A1 (en) * 2020-05-26 2021-12-02 Baylor College Of Medicine Novel soluble epoxide hydrolase inhibitors and method of use thereof
WO2022007882A1 (zh) * 2020-07-09 2022-01-13 苏州爱科百发生物医药技术有限公司 一种atx抑制剂及其制备方法和应用
CN114380817A (zh) * 2020-10-21 2022-04-22 中国医学科学院药物研究所 苯并咪唑并2-氨基-1,3,4-噻二唑化合物及其制法和药物用途
KR20240031300A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널 조절제로서의 n-(하이드록시알킬 (헤테로)아릴) 테트라하이드로푸란 카르복스아미드
AU2022306297A1 (en) 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
WO2024017381A1 (zh) * 2022-07-22 2024-01-25 深圳众格生物科技有限公司 一种抑制irak4活性的化合物及其应用
CN115850258A (zh) * 2022-12-27 2023-03-28 东北林业大学 一种马赛替尼的合成方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
FR2751649B1 (fr) 1996-07-26 1998-08-28 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
JP2001522853A (ja) 1997-11-11 2001-11-20 ファイザー・プロダクツ・インク 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体
PL215901B1 (pl) * 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
DK1525200T3 (da) 2002-08-02 2007-12-03 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoler til sygdomsbehandling
CA2523126A1 (en) * 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
WO2005021537A1 (en) * 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
MX2007007704A (es) 2004-11-23 2007-09-14 Reddy Therapeutics Inc Compuestos heterociclicos biciclicos novedosos, procesos para su preparacion y composiciones que los contienen.
ES2316053T3 (es) 2005-02-10 2009-04-01 Smithkline Beecham Corporation Compuestos de piridopirazolopirimidina y sus usos como farmacos contra el cancer y contra la diabetes.
WO2007081630A2 (en) * 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Substituted pyrimidinyl kinase inhibitors
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
EP1878733A1 (en) 2006-07-14 2008-01-16 Novartis AG Pyrimidine derivatives as ALK-5 inhibitors
PT2078010E (pt) * 2006-12-29 2014-05-07 Rigel Pharmaceuticals Inc Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
WO2009084695A1 (ja) * 2007-12-28 2009-07-09 Carna Biosciences Inc. ２－アミノキナゾリン誘導体
DK2294066T3 (da) * 2008-04-28 2014-09-08 Janssen Pharmaceutica Nv Benzoimidazoler som prolylhydroxylaseinhibitorer
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基***并吡啶，其組合物及使用其之治療方法
CA2744935A1 (en) 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh New compounds
AU2010224693B2 (en) 2009-03-19 2016-07-28 Lifearc Compounds
US8486933B2 (en) 2009-05-27 2013-07-16 Abbvie Inc. Pyrimidine inhibitors of kinase activity
JP5607241B2 (ja) * 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
WO2012044090A2 (ko) * 2010-09-29 2012-04-05 크리스탈지노믹스(주) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
JP5959537B2 (ja) 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
CA2830129C (en) * 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
MX363696B (es) * 2011-04-21 2019-03-28 Origenis Gmbh Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas.

Also Published As

Publication number Publication date
US10202370B2 (en) 2019-02-12
EP3010906B1 (en) 2019-06-12
WO2014202763A1 (en) 2014-12-24
TW201534597A (zh) 2015-09-16
AR096654A1 (es) 2016-01-27
EP3010906A1 (en) 2016-04-27
US20160152608A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
HRP20181429T8 (hr) Novi derivati benzimidazola kao inhibitori kinaze
HK1222646A1 (zh) 作為溴結構域抑制劑的苯並咪唑衍生物
HK1220692A1 (zh) 作為布羅莫結構域抑制劑的苯並咪唑酮衍生物
HK1222396A1 (zh) 作為選擇性蛋白質激酶抑制劑之苯並咪唑衍生物
SG11201600062RA (en) Pyrimidine derivatives as kinase inhibitors
ZA201406078B (en) Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors
EP2981535B8 (en) Urea derivatives useful as kinase inhibitors
IL245660A0 (en) History of aminopyridines as tam family kinase inhibitors
HK1211578A1 (zh) 作為 激酶抑制劑的酰氨基咪唑並噠嗪
HK1232227A1 (zh) 作為 抑制劑的喹嗪酮衍生物
HK1258911A1 (zh) 可用作c-fms激酶抑制劑的取代的吡啶衍生物
HK1213885A1 (zh) 作為 抑制劑的咪唑並-三嗪衍生物
EP2968324A4 (en) SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS